Medincell shares dive 15% as FY26 loss widens, AbbVie trial delayed

Investing.com Gold reports: Medincell shares dive 15% as FY26 loss widens, AbbVie trial delayed. Full body text was unavailable at ingest time, so this brief is based on headline context.